GEN-MKT-18-7897-A
Feb 7, 2025 | Blogs, Pharma, ZenoTOF 7600 system | 0 comments
Read Time: 2 Minutes
Liquid chromatography-mass spectrometry is commonly used for Met ID but confident soft spot identification is not always possible. Imagine the advantage of unambiguous metabolite identification using liquid chromatography-mass spectrometry (LC-MS) reducing the need for additional safety testing during drug discovery. Quickly and easily generate the information you need using routine assays that are robust and efficient, enabling confident decision-making while also saving time and money. Learn more >
Metabolite identification is a key task during drug discovery to establish safety and efficacy of a drug candidate. LC-MS assays for metabolite identification typically use collision-induced dissociation (CID) to fragment ions for structural elucidation, and soft-spot identification. With challenging metabolites, CID doesn’t produce sufficient fragment ions or help with labile modifications and a clear identification cannot be made. This can lead to the need for additional testing to meet regulatory requirements.
EAD is a fragmentation method available on the ZenoTOF 7600 system that causes ions in an LC-MS/MS experiment to fragment in locations that are different from where they fragment with CID, providing additional information to scientists. For metabolite identification, this could mean confident identification of the metabolite and localization of the site of metabolism, removing the need for additional safety testing.
Curious to know more? Watch our on-demand Met ID webinars, here? LINK WILL COME FROM HERE https://sciex.kapost.com/posts/pharma-webinar-content-hub-lp-and-typ
As regulatory scrutiny increases and detection requirements tighten, laboratories are facing a new question: How can TFA be measured reliably, sensitively, and at scale?
Glycosylation is one of the more structurally diverse and biologically impactful PTMs in protein therapeutics. Both N‑linked and O‑linked glycans influence protein folding, stability, and biological activity. Given these effects on biotherapeutics, glycosylation is a closely monitored critical quality attribute (CQA). Comprehensive and site‑specific characterization of glycosylation is essential for informed decision‑making throughout drug discovery and development.
Warranty expiration is more than an administrative milestone—it is a transition point that can significantly impact instrument uptime, laboratory productivity, operating budgets, and scientific outcomes.
Posted by
You must be logged in to post a comment.
Share this post with your network